The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Biohit Oyj’s Chinese Joint Venture to Start Production
Oct. 24, 2016 01:29AM PST
Medical Device InvestingBiohit Oyj’s Chinese joint venture Biohit HealthCare (Hefei) Co. Ltd production facility has passed official test requirements and has been granted a license enabling production and sales of products.
Biohit Oyj’s Chinese joint venture Biohit HealthCare (Hefei) Co. Ltd production facility has passed official test requirements and has been granted a license enabling production and sales of products.
Biohit HealthCare (Hefei) Co. Ltd will start manufacturing of the globally unique GastroPanel®-products developed by Biohit Oyj for the Chinese market, and the first shipments will go to fill orders relating to the ongoing gastric cancer risk screening study which has been expanded to cover over 150 hospitals and expected to be concluded by the end of 2016 on part of the patient screening. The study will continue with statistical data analysis and reporting from various municipalities and hospitals that have taken part in the study. The reporting and analysis phase is expected to be completed during 2017. The results of the analysis will determine if a population based screening program is feasible. In the meantime sales of GastroPanel®-tests has continued in the 14 provinces where price approval has been granted. Biohit Oyj will supply the necessary raw materials and reagents used in production.
CEO Semi Korpela, Biohit Oyj: ‘The approval and official permit process have taken longer than anticipated, but are finally completed. Our joint venture can now produce GastroPanel®-products for the promising Chinese markets cost effectively and in large scale. The GastroPanel® (1,2), which is highly informative and unique in China and elsewhere in the world doesn’t have the serious medical deficiencies as do the helicobacter tests (e.g. 13C urea breath test) still in use (3).’
CEO Liu Feng, Biohit HealthCare (Hefei) Co. Ltd: ‘We have finalised the production facility utilising state of the art technology and process automation for the production, warehousing and logistics of GastroPanel®-products for the Chinese domestic market. The production capacity has been tailored to correspond with the capacity needs of a possible population based screening program.’
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
1. www.biohithealthcare.com/additional-information
2. www.gastropanel.com/decision-makers/screening-model
3. https://www.biohithealthcare.com/limitations-of-helicobacter-pylori-diagnostics
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.